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these reports may be the result of publication bias, i.e., it appears
that multiple groups have looked at this issue, but only those
groups that have found a signiﬁcant relationship, potentially as a
result of random chance, have reported their ﬁndings. To further
investigate this question we developed a multivariate logistic re-
gression model for factors predictive of acute GVHD based on a
series 167 patients, including 18 African-Americans, who under-
went allogeneic BMT at our institution between January 1, 1992
and May 30, 2004. Factors examined in the multivariate model
included age, CD34 dose, CD3 dose, sex mismatch pattern (fe-
male-to-male vs other), category of conditioning regimen (full-
dose vs reduced-dose), presence or absence of an antigen-level
HLA mismatch, type of donor (related vs unrelated), stem cell
source (marrow vs PBSC), and race (African-American vs Cauca-
sian). It was not possible to separate out the potential effect of the
GVHD prophylactic regimen because our data set is characterized
by a very strong correlation between type of GVHD prophylactic
regimen and category of conditioning regimen. We observed a
univariate trend toward an increased incidence of Grade 3 or
higher acute GVHD among African Americans (39% vs 21%, p 
0.13). Race was not independently predictive of acute GVHD in
the multivariate model, although the statistical power of the model
to detect this relationship was limited due to the fact that only 18
African Americans were included in the series. Interestingly,
among patients transplanted since 1996, there was a statistically
signiﬁcant (univariate) increase in the incidence of grade 3 or
higher acute GVHD among African Americans (64% vs 25%, p 
0.01) but also a parallel disparity in the incidence of HLA-mis-
matched transplantation (27% vs 6%, p  0.036) such that race
remained non-contributory in the multivariate model. We con-
clude that the purported relationship between race and acute
GVHD may be less strong that has been previously reported due to
publication bias and/or to an increased incidence of HLA-mis-
matched transplant in this population. Further examination of this
issue using larger data sets appears warranted.
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Introduction: Chronic graft-versus-host disease (cGVHD) is a
major cause of long term morbidity and mortality following allo-
geneic hematopoietic stem cell transplant (HSCT). Beyond the
combination of steroids and calcineurin inhibitors, a variety of
immunosuppressive methods have been used to manage this con-
dition, most of them of limited efﬁcacy and steroid-sparing capac-
ity. ECP is becoming increasingly used in the treatment of acute
and chronic GVHD, with promising preliminary data. Methods:
Retrospective evaluation of all ECP procedures performed be-
tween 1/30/98 and 10/2/92 in patients with GVHD occurring after
day 100. Patients were considered evaluable for response when
they were treated with ECP for at least 1 month, without the
addition of any further immunosuppression. Complete (CR) and
partial responses (PR) had a minimal duration of 2 weeks. Results:
A total of 82 patients with chronic GVHD were analyzed. The
median age was 40 (5–70), and the donor origin was matched
sibling (48, 59%), matched unrelated (24, 29%) or mismatched
(10) HSCT. Most of them received tacrolimus-based prophylaxis
(74, 90%) and had a history of acute GVHD (64, 78%). Most
patients were on steroids (64) and had received a median of 2 (1–6)
treatments prior to ECP. Out of 82 patients, only 51 were evalu-
able for response, and the remainder received further immunosup-
pression within a month from the start of ECP (30), or lacked
documentation (1). The CR/PR rate for evaluable patients was
82% (n 42). Thirty-four patients (67%) had skin involvement
and the majority (32, 94%) responded to ECP. All types of skin
involvement (lichenoid, scleroderma, mixed, acute-appearing) re-
sponded to therapy. ECP also demonstrated activity in visceral
GVHD, with response rates of (15, 88%) and (6, 67%) respec-
tively. The CR/PR rate for oral GVHD was 100% (n 6), and for
ocular GVHD 75% (n 3). Of 51 patients, 32 required further
immunosuppression for control of their GVHD. Since initiation of
ECP, the overall survival for the whole group was 37%, with a
median survival of 10 months. Conclusions: In this heavily pre-
treated group of patients with chronic GVHD, the response to
ECP seems promising in all organs, including GVHD of the lung
and the liver. The prospective and systematic evaluation of the role
of ECP in the management of GVHD is warranted.
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SUBEROYLANILIDE HYDROXAMIC ACID MODULATES THE INNATE AND
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LATES EXPERIMENTAL ACUTE GRAFT-VERSUS-HOST DISEASE
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Dendritic cells modulate the innate (via Toll like receptors-
TLRs) and the allostimulatory immune responses. Suberoylanilide
hydroxamic acid (SAHA) is an anti-tumor agent that also exhibits
potent anti-inﬂammatory properties. We investigated the effect of
SAHA on modulating DC functions. Pre-incubation of BM de-
rived DCs with 100 nM-500 nM concentrations of SAHA (s-DCs)
signiﬁcantly reduced the secretion of TNF- and IL-6 upon TLR
stimulation with lipopolysaccharide (TLR-4), peptidoglycan
(TLR-2), poly IC (TLR-3) and CpG (TLR-9). Pre-treatment of
DCs with SAHA signiﬁcantly reduced the proliferation of alloge-
neic T cells in MLR cultures. Mixing experiments at 1:1 ratio
signiﬁcantly suppressed the allostimulatory capacity of control
DCs. Incubation of DCs with SAHA signiﬁcantly decreased the
expression of CD40, CD80, CD86 and OX40L and but caused no
signiﬁcant changes in MHC class II expression. We determined
the in vivo relevance of SAHA mediated effects on DCs by utilizing
Class I disparate CD8mediated [bm13 2MG/], and Class II
disparate CD4 mediated [bm12 3 MHC-II/] murine models
of alloreaction. Recipient 2MG/ and Class-II/ B6 animals
received 11 Gy, 2–4 106 T cells and 5 106 TCDBM cells from
syngeneic B6 or allogeneic bm-1 and bm-12 donors respectively.
The recipients were also injected on days1 and 0 with 4–5 106
wild type B6 BM derived c-DC and s-DCs. Injection of s-DCs
signiﬁcantly reduced in vivo allogeneic donor T cell expansion of
both CD4 and CD8 T cell subsets. We next utilized the well
characterized mouse [BALB/c 3 B6] model of acute GVHD to
determine the effect of s-DCs on an ongoing GVHD reaction. On
day1, the recipient B6 animals received 11 Gy and on day 0 were
injected with 2  106 T cells and 5  106 BM cells from syngeneic
B6 or allogeneic BALB/c donors. Injection of 5  106 host type
s-DCs on days 1, 0, and 2 resulted in signiﬁcantly better
survival, reduced serum levels of TNF-, donor T cell expansion
and histopathology of GVHD (P 
 0.01) on day 7 after BMT.
Lastly, we determined the effect of SAHA on the DCs derived
from the peripheral blood of normal healthy human volunteers and
found that SAHA signiﬁcantly reduced allogeneic T cell prolifer-
ation. Together our results demonstrate that SAHA modulates
innate and allostimulatory functions of DCs in vitro and in vivo,
and suggest that SAHA treatment of DCs might represent a novel
cellular therapy that can reduce clinical GVHD.
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MATURE T CELLS ALONE SEPARATE GVL FROM GVHD: THE NEED FOR
BETTER CONTROLS
Chen, B.J.; Son, J.; Cui, X.; Chao, N.J. Duke University Medical
Center, Durham, NC.
Separation of graft-vs.-leukemia effect (GVL) from graft-vs.-host
disease (GVHD) is the phenomenon that patients with leukemia/
lymphoma achieve complete remission without GVHD after allo-
geneic stem cell transplantation. We demonstrate in this study that
separation of GVL from GVHD could be achieved using only
unmanipulated mature T cells in a mouse model. Graded numbers
(103-106) of puriﬁed T cells from C57BL/6 mice were transplanted
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